Den europeiske union - norsk - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotic agents - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antithrombotic agents - forebygging av venøs tromboembolisme (vte) hos voksne pasienter som gjennomgår valgfri hofte- eller kneutskifting. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. (see section 4. 4 for haemodynamically ustabil pe pasienter). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 og 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Norge - norsk - Statens legemiddelverk

mylan healthcare norge as - klaritromycin - granulat til mikstur, suspensjon - 25 mg/ ml

Norge - norsk - Statens legemiddelverk

mylan healthcare norge as - klaritromycin - granulat til mikstur, suspensjon - 50 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antithrombotic agents - xarelto, co-gis med acetylsalisylsyre (asa) alene eller sammen med asa pluss clopidogrel eller tiklopidin, er indikert for forebygging av atherothrombotic hendelser hos voksne pasienter etter et akutt koronar syndrom (acs) med forhøyet ved biomarkører. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. forebygging av venøs tromboembolisme (vte) hos voksne pasienter som gjennomgår valgfri hofte- eller kneutskifting. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Norge - norsk - Statens legemiddelverk

orifarm as - klaritromycin - depottablett - 500 mg

Norge - norsk - Statens legemiddelverk

viatris as - klaritromycin - depottablett - 500 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - narkotika-relaterte bivirkninger og uønskede reaksjoner - alle andre terapeutiske produkter - for voksne pasienter behandlet med en direkte faktor xa (anl) inhibitor (apixaban eller rivaroxaban) når reversering av antikoagulasjonsbehandling er nødvendig på grunn av livstruende eller ukontrollert blødning.

Den europeiske union - norsk - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Norge - norsk - Statens legemiddelverk

amdipharm limited - erytromycinetylsuksinat - granulat til mikstur, suspensjon - 100 mg/ ml